Aurora kinase inhibitors: identification and preclinical validation of their biomarkers.
about
Aurora Kinase Inhibitors: Current Status and OutlookProtein kinase inhibitors against malignant lymphomaInhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cellsAurora kinases in head and neck cancerThe aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumorsEfficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patternsPredictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.Advances in Aurora kinase inhibitor patents.Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.Targeting aneuploid cancer cells.Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer.HIPK2 and extrachromosomal histone H2B are separately recruited by Aurora-B for cytokinesis.
P2860
Q26770583-20A6EAA1-4FA2-4EF8-A799-4BD17F6E3649Q27024212-78F2E5B0-1DA4-478C-81A0-4EC8102006A8Q28545195-FC09FF72-F29B-4D1C-8E42-35E548DE221DQ28654389-EDF52CB0-9B2F-4A47-A1AB-8E71E36F202EQ34981765-47C41082-528D-4BF8-9A32-A00170E72ADCQ35289072-04CA5F95-26F3-4703-9390-F0BFDCD62C2DQ35549470-F4153ED9-4BD3-44B0-996F-6114AF4CA132Q36469916-6D41E7AA-104D-493D-AE51-AEE03C60E16FQ36511204-8D759B18-A4B3-4CDC-9C28-CF22C34573C7Q36726212-918185DE-CCC1-47BA-9E02-6A185E50346DQ37401839-28ADD0CA-DBD2-44A6-A65B-6933A68BC52CQ37481268-D115B6CC-D94C-441F-BFB5-3834A9BA65E6Q37690579-98920AD5-8C17-4B20-A3D0-04A6462CAA15Q37840163-2B8E9C0B-D4A6-4ABE-A6D3-3871FEC208B5Q39571840-BF5251EB-60F6-4B0B-9FEF-63E25FC12103Q39608458-FB79C80D-AA04-4B2A-9AEB-BCD31AA92CBAQ46916025-242983CE-8880-47DC-BD7B-301204BCF868Q52725117-1F97449E-4E15-49B8-AC0E-22DE22E05711
P2860
Aurora kinase inhibitors: identification and preclinical validation of their biomarkers.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Aurora kinase inhibitors: identification and preclinical validation of their biomarkers.
@en
Aurora kinase inhibitors: identification and preclinical validation of their biomarkers.
@nl
type
label
Aurora kinase inhibitors: identification and preclinical validation of their biomarkers.
@en
Aurora kinase inhibitors: identification and preclinical validation of their biomarkers.
@nl
prefLabel
Aurora kinase inhibitors: identification and preclinical validation of their biomarkers.
@en
Aurora kinase inhibitors: identification and preclinical validation of their biomarkers.
@nl
P2860
P356
P1476
Aurora kinase inhibitors: identification and preclinical validation of their biomarkers.
@en
P2093
Jürgen Moll
Patrizia Carpinelli
P2860
P356
10.1517/14728222.12.1.69
P407
P577
2008-01-01T00:00:00Z